Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all
Completed Phase 3 Interventional Results available

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

NCT02971683
View directory record Official record
Conditions
Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
Interventions
Abatacept subcutaneous, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 24, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

NCT02303041
View directory record Official record
Conditions
Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Interventions
Buparlisib, Sonidegib
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

NCT00147966
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
rituximab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 24, 2026, 4:21 PM EDT
Terminated Not applicable Interventional Results available

A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

NCT01140503
View directory record Official record
Conditions
Dermatomyositis
Interventions
Apremilast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 24, 2026, 4:21 PM EDT
Completed No phase listed Observational

Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients

NCT01288586
View directory record Official record
Conditions
Primary Arthrosis
Interventions
Scandinavian Total Ankle Replacement System (STAR Ankle)
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Oakland, California • Temple Terrace, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 24, 2026, 4:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine

NCT04310462
View directory record Official record
Conditions
Rheumatic Diseases
Interventions
New e-prescribing interface
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

NCT02277574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMP-110, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants

NCT01202760
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
77
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 24, 2026, 4:21 PM EDT
Terminated Not applicable Interventional

Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee

NCT04537013
View directory record Official record
Conditions
Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort
Interventions
Microfracture, Microfracture plus placement of Chondro-Gide® ACC
Procedure · Device
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Stamford, Connecticut • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

NCT02762123
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986142 200mg, BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin), BMS-986142 350mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789
View directory record Official record
Conditions
TGCT
Interventions
Emactuzumab, Placebo
Drug
Lead sponsor
SynOx Therapeutics Limited
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Beverly Hills, California • Los Angeles, California • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

NCT00642460
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 24, 2026, 4:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Clinical Outcomes and Performance of Total Knee Replacement Patients Before and After Surgery

NCT01379118
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis, Knee Injury, Trauma, Connective Tissue Disorder, Pain, Loss of Function
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Results available

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

NCT01904279
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

RASopathy Biorepository

NCT04395495
View directory record Official record
Conditions
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2065
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Optimizing the Management of Flares in Patients With Rheumatoid Arthritis (RA)

NCT02382783
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
FLARE Intervention Group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

NCT01768975
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
OLT1177 Gel, Placebo gel
Drug · Other
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
DeLand, Florida • South Miami, Florida • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

NCT02165345
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 24, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA

NCT05003934
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 4:21 PM EDT